

Antibiotic Allergy in Practice

Immunocompromised Hosts & Hospitalised Patients

30th January 2021, Peter MacCallum Cancer Centre, Melbourne, Australia



A half-day online workshop from international experts aiding the practical implementation of antibiotic allergy knowledge, assessment and testing in hospital practice of the immunocompromised and vulnerable host.

Date: 30th of January 2021

Format: Online interactive workshop

Local Conveners: **A/Prof Jason Trubiano** (Centre for Antibiotic Allergy and Research, AUS)
Ms. Misha Devchand (AMS Pharmacist, Austin Health, AUS)
Centre for Antibiotic Allergy and Research (AUS) @CAAR_Aus

International: Prof Elizabeth Phillips (USA), Dr Kimberly Blumenthal (USA), Ms Mary Staicu (USA), A/Prof Jonny Peter (South Africa), Dr Ana Copaescu (Canada) - *Biographies page 2.*

Info & Ticketing: <https://cancerandinfections.org/calendar/2020/11/11/ncicsymposium2021>

0800	Welcome and Introduction	A/Prof Jason Trubiano Convener, Austin Health (AH)
Session 1 – Chairs: Dr Natasha Holmes & A/Prof Jason Trubiano		
0815	Antimicrobial allergy in HIV and tuberculosis <i>HIV, mycobacterial infections and immunocompromised hosts</i>	A/Prof Jonny Peter Head of the Division of Allergology and Clinical Immunology at Groote Schuur Hospital (South Africa)
0845	Demystifying rashes - which drug and what phenotype <i>Antibiotic and chemotherapeutic toxicities</i>	Dr Michelle Goh Dermatologist - Alfred Health (AH) & Peter MacCallum
0915	Antibiotic allergy assessment tools in hospital practice <i>The pharmacist role in antibiotic allergy</i>	Ms Misha Devchand AMS and Antibiotic Allergy Pharmacist - AH
0945	Antimicrobial allergy cross-reactivity – β-lactams & beyond <i>Implications for antibiotic & antifungal guidelines in high-risk hosts</i>	Dr Ana Copaescu Allergist/Immunologist McGill University, Canada
1010	BREAK	
Session 2: - Chairs: Ms Misha Devchand & Dr Kyra Chua		
1020	Digital health solutions to antibiotic allergy <i>EMR and Telehealth solutions</i>	Ms Mary Staicu AMS Pharmacist – Rochester General Hospital NY, USA
1040	Antibiotic allergy in surgery <i>Preventing surgical site infections & enhancing antimicrobial stewardship</i>	Dr Kimberly Blumenthal Allergist and Immunologist Massachusetts General Hospital, USA
1110	Severe Cutaneous Adverse Reactions <i>Epidemiology, diagnostics and genomic predictors for the bedside</i>	Prof Elizabeth Phillips Professor of Medicine - Vanderbilt University, USA
1140	Inpatient antibiotic allergy testing programs <i>Pathways to direct oral challenge programs and inpatient testing</i>	A/Prof Jason Trubiano Director of AMS & Drug and Antibiotic Allergy Services - AH
1210	Meet the Experts <i>Interactive case scenarios and questions</i>	Cases presented by clinicians and fellows of Centre for Antibiotic Allergy and Research
1240	CLOSE	



International speakers



Prof Elizabeth Phillips MD FIDSA FAAAAI @vumc_cdsi_rsch
*John A.Oates Chair in Clinical Research; Professor of Medicine, Pharmacology Pathology, Microbiology & Immunology
Centre for Drug Safety and Immunology, Vanderbilt University Medical Centre*

World leader in translational drug hypersensitivity who has pioneered the discover and implementation of immunogenomic predictors, immunopathogenesis and novel technologies into clinical practice. She has led clinical and research programs in drug hypersensitivity across different medical systems for over 25 years



Dr Kimberly Blumenthal MD MSc @KimberlyBlumen1
Allergist/Immunologist (USA)

Is a drug allergy researcher at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. She is the Co-Director of the Clinical Epidemiology Program within the Division of Rheumatology Allergy and Immunology and the Quality and Safety Officer for Allergy at the Edward P. Lawrence Center for Quality and Safety. Dr. Blumenthal performs drug allergy research that uses methods of epidemiology, informatics, economics, and decision science. Dr. Blumenthal is recognized nationally for identifying the morbidity and mortality associated with unverified penicillin allergy and creating innovative approaches to the evaluation of penicillin and cephalosporin antibiotic allergies in the hospital setting. Dr. Blumenthal has authored more than 90 peer-reviewed publications including in high-impact journals Lancet, JAMA, and BMJ.



A/Prof Jonny Peter MB ChB MMed FCP (SA) PhD @JonnyPeter7
Allergist/Immunologist (South Africa)

A specialist in internal medicine at the Groote Schuur Hospital, University of Cape Town and the Allergy and Immunology unit, UCT Lung Institute. Current clinical and research interests include: i) immune-mediated adverse drug reactions ii) urticaria and angioedema, as well as the intersection between COVID-19 and immunogenomic pathways associated with Angioedema iii) primary immunodeficiencies, and iv) the aerobiology of South Africa. Jonathan has over 80 publications in high impact factor journals, and H-index od 36. His research work is supported by grant funding from the NIH, EDCTP, SA NRF & MRC.



Ms Mary L Staicu Pharm.D., BCIDP @marylynnstaicu
Infectious Diseases Clinical Pharmacy Specialist (USA)

Is an Infectious Diseases Clinical Pharmacy Specialist practicing at Rochester General Hospital in Rochester, NY. In her current position, Mary is a founding and active member of the Antimicrobial Stewardship Team and serves on various hospital and system-wide committees, striving to promote the appropriate use of antimicrobial agents through clinical stewardship interventions, program and guideline development, and active research. Although involved in multiple antimicrobial stewardship research projects, her specific area of interest is the clinical and economic implications of the penicillin allergy label.



Dr Ana Copaescu MD FRCPC @AnaCopaescu
Clinician-Scientist (Canada)

An allergy-immunology and internal medicine specialist at the McGill University Health Center in Montreal, Canada. She has completed a Fellowship in Drug and Antibiotic Allergy at the Austin Health, Melbourne, Australia (Centre for Antibiotic Allergy and Research) and is currently a PhD candidate in delayed drug allergy immune-mediated hypersensitivity reactions with an interest for the severe phenotypes.